This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts
by Zacks Equity Research
OPKO Health beats Q4 earnings and revenue estimates, but sales decline and gross margin narrows.
BSXPositive Net Change OPKNo Net Change HQYNegative Net Change SOLVNegative Net Change
earnings medical medical-devices
Solventum Stock Down Despite Q4 Earnings & Revenues Beat, Margins Down
by Zacks Equity Research
SOLV's Q4 earnings and revenues beat estimates, driven by organic growth across MedSurg, Dental and HIS, despite margins declined.
CAHPositive Net Change MCKPositive Net Change GEHCPositive Net Change SOLVNegative Net Change
earnings medical medical-devices
Clover Health Q4 Earnings Meet Estimates, Sales Beat, Membership Rises
by Zacks Equity Research
CLOV Q4 loss matches estimates. Revenues jump 45%. The 2026 outlook calls for up to 49% growth and potential GAAP profitability.
ANGONegative Net Change ISRGNegative Net Change ALCPositive Net Change CLOVNegative Net Change
earnings medical medical-devices
Universal Health's Q4 Earnings Miss on Softer Volumes & Rising Costs
by Zacks Equity Research
UHS' Q4 EPS misses estimates despite a 19.5% jump, as softer admissions and rising costs weighed on results even as revenues climbed 9.1%.
UHSPositive Net Change HCAPositive Net Change ENSGPositive Net Change EHCPositive Net Change
earnings medical
Hims & Hers Expands Digital Health and Global Platform Strategy
by Debanjana Dey
HIMS expands into labs, cancer screening, menopause and global markets, advancing its digital, subscription-driven healthcare platform and preventive care.
GDRXNegative Net Change HIMSNegative Net Change LFMDNegative Net Change
medical medical-devices
CHE Stock Falls Post Q4 Earnings & Revenue Miss, Margins Crash
by Zacks Equity Research
Chemed slips 15% as Q4 earnings and revenue missed estimates, margins contracted, and the 2026 EPS outlook fell short of consensus.
ISRGNegative Net Change ALGNPositive Net Change CAHPositive Net Change CHEPositive Net Change
earnings medical medical-devices
GEHC & UCSF Form 10-Year Alliance to Advance Imaging & Care Delivery
by Zacks Equity Research
GE HealthCare inks a 10-year Care Alliance with UCSF Health to expand advanced imaging, boost MR excellence and strengthen long-term revenue visibility.
ISRGNegative Net Change CAHPositive Net Change VCYTNegative Net Change GEHCPositive Net Change
medical medical-devices
Zacks.com featured highlights include Crocs, LATAM Airlines, Arrow Electronics and Phibro Animal Health
by Zacks Equity Research
Crocs, LATAM Airlines, Arrow Electronics and Phibro screen cheap on PEG ratios, pairing solid growth outlooks with value appeal in volatile markets.
ARWNegative Net Change CROXNegative Net Change LTMNegative Net Change PAHCNegative Net Change
computers consumer-discretionary medical transportation
Jazz Pharmaceuticals' CBD Drug Hits $1B: Time to Buy the Stock?
by Sundeep Ganoria
JAZZ CBD drug Epidiolex tops $1B in annual sales, boosting revenue visibility and cannabis exposure. Is the biotech's growth story just beginning?
JAZZPositive Net Change TLRYNegative Net Change ACBNegative Net Change
biotechs marijuana medical pot-stocks
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down
by Zacks Equity Research
PCRX misses Q4 earnings and revenue estimates as expenses surge and shares slide, despite Exparel growth and a new 2026 outlook.
PCRXNegative Net Change USNAPositive Net Change CSTLNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals